Michigan Healthcare Professionals

Recent papers from Michigan Healthcare Professionals

1. Validation of a multi-omic biosignature for locoregional recurrence and radiation therapy benefit in breast cancernpj Breast Cancer · 2026
2. Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate CancerJAMA · 2026
3. Cohort-level safety and efficacy results for [ ²¹² Pb]VMT-α-NET in advanced somatostatin receptor subtype 2 (SSTR2+)–expressing neuroendocrine tumors (NETs): Cohorts 1–3.Journal of Clinical Oncology · 2026
4. 191P Automated contouring (AC) of cardiac substructures using AI-based algorithms on whole breast radiation therapy (RT) CT-scans for NRG oncology RTOG 1005 (R1005)ESMO Open · 2026
5. Predictors of Medication Cessation After Benign Prostatic Hyperplasia ProceduresThe Journal of Urology · 2026
6. Concurrent Versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of High-Risk Early Breast Cancer: NRG/RTOG 1005 Phase III TrialJournal of Clinical Oncology · 2026
7. A randomized phase 2 study of enhanced AR blockade with enzalutamide in high-risk patients with biochemical relapse undergoing salvage radiation: Final results from RTOG 3506 (STEEL).Journal of Clinical Oncology · 2026
8. Re: Self-Collected Vaginal Specimens at Home for HPV Testing: Recommendations From the Enduring Guidelines CommitteeJournal of Lower Genital Tract Disease · 2026
9. Abstract PS2-08-16: Validation of a multi-omic biosignature to predict locoregional recurrence risk and the benefit of adjuvant radiation therapy in women with early-stage invasive breast cancer treated with breast-conserving surgery and endocrine therapyClinical Cancer Research · 2026
10. Development and cross-validation of a novel multi-omic assay to assess locoregional recurrence risk and adjuvant therapy benefit in early-stage hormone receptor positive invasive breast cancer patientsBreast Cancer Research · 2026
11. Safety and preliminary efficacy results of [ ²¹² Pb]VMT-a-NET in advanced somatostatin receptor subtype 2 (SSTR2)-expressing neuroendocrine tumors (NETs).Journal of Clinical Oncology · 2026
12. Assessing Quality and Adherence to PI‐RADSv2.1 Minimum Technical Standards of Prostate MRI in NRG‐GU005Journal of Magnetic Resonance Imaging · 2025
13. The Importance of a Pre-treatment Baseline When Screening Patients for Breast-Cancer-Related LymphedemaAnnals of Surgical Oncology · 2025
14. Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women With Low-Risk Ductal Carcinoma In Situ After Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-Year Ipsilateral Breast Recurrence RatesInternational Journal of Radiation Oncology*Biology*Physics · 2025
15. Omitting Regional Nodal Irradiation after Response to Neoadjuvant ChemotherapyNew England Journal of Medicine · 2025
16. Predictors of Initial Response of Thyroid Nodules Treated With RFA, a Multi-Endocrinology Centers Experience From the United StatesJournal of the Endocrine Society · 2025
17. Self-Collected Vaginal Specimens for HPV Testing: Recommendations From the Enduring Consensus Cervical Cancer Screening and Management Guidelines CommitteeJournal of Lower Genital Tract Disease · 2025
18. ACROPath Oligometastases: The American College of Radiation Oncology Clinical PathwayCureus · 2024
19. Quality-of-Life Outcomes from NRG/NSABP B-39/RTOG 0413: Whole-breast Irradiation vs Accelerated Partial-breast Irradiation after Breast Conserving SurgeryJNCI Journal of the National Cancer Institute · 2024
20. A 7-Gene Biosignature for Ductal Carcinoma in situ of the Breast Identifies Subpopulations of HER2-positive Patients With Distinct Recurrence Rates After Breast-Conserving Surgery and Radiation TherapyClinical Breast Cancer · 2024